Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial

This publication has 25 references indexed in Scilit:

• A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
  New England Journal of Medicine, 2020
• Inflammatory side effects of BRAF and MEK inhibitors
  Melanoma Research, 2019
• Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors
  JAMA Network Open, 2019
• OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS
  Retina, 2019
• Comparison of antiviral resistance across acute and chronic viral infections
  Antiviral Research, 2018
• The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo
  Antiviral Research, 2017
• MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity
  Eye, 2015
• Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo
  Antiviral Research, 2011
• RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade
  Biological Chemistry, 2008
• Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade
  Nature Cell Biology, 2001